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The Notch pathway and the endocrine system constitute two key biological 
signaling mechanisms, responsible for cell-to-cell communication between adjacent 
cells and long-distance hormonal signals respectively. They play central roles during the 
development of higher eukaryotic organisms but they also take part in the regulation of 
many aspects of adult physiology and homeostasis. The contribution of defects in the 
normal transmission of hormone-dependent signals to the development of endocrine 
cancers has been widely analyzed and the knowledge derived from these studies has 
allowed us to develop many successful therapeutic strategies. However, in many cases 
these hormonal treatments become ineffective despite the fact that cancer cells maintain 
normal expression levels of wild-type hormone nuclear receptors. Less is known about 
the involvement of altered Notch signaling in the origin and progression of cancer, 
although there is clear evidence indicating that deregulation of Notch activity occurs in 
several types of tumors, including highly prevalent hormone-dependent types of cancer 
such as breast, ovarian and prostate cancer. This review will summarize accumulating 
data suggesting that Notch signaling plays a key role in the control of proliferation, 
differentiation and survival of prostate epithelial cells. Notch signals are required for 
normal prostate development and homeostasis, and abnormalities in Notch signaling 
may be critical during the development of prostate cancer. We will also discuss the 
possible oncogenic role for alterations in the crosstalk mechanisms between Notch and 
androgen-dependent signals during tumorigenesis in the prostate and how they could 
influence the outcome of anti-cancer hormonal treatments. 
INTRODUCTION 
The prostate is an exocrine gland of the male mammalian reproductive system, the 
primary function of which is to produce seminal fluids and it is also required for bladder 
control and normal sexual functioning. The development and homeostatic maintenance 
of the prostate are both regulated by an interplay between endocrine hormones, 
paracrine signals and local cell-cell interactions that modulate the specific genetic 
pathways controlling cell proliferation and differentiation (reviewed in [1]). Alterations 
in these complex regulatory networks contribute to the abnormal cell physiology 
responsible for benign prostate hyperplasia (BPH), prostatic intraepithelial neoplasia 
(PIN) and malignant prostate tumors [2-4]. Prostate cancer (PC) is the most frequently 
diagnosed neoplasm and the second leading cause of cancer-related death in men in 
western countries [5], therefore much effort has been devoted to studying its etiology 
and to developing effective therapies against this disease. The prostate consists of 
glandular epithelium surrounded by fibromuscular stroma. Over 90% of prostate tumors 
arise within the glandular epithelial cell compartment [6]. For that reason, the 
elucidation of the molecular mechanisms that regulate epithelial cell proliferation and 
differentiation is an essential step towards understanding the basis of oncogenic 
transformation in the prostate gland. Among the endocrine hormones, androgens play a 
pivotal role in PC etiology because they are required for prostate epithelial cell growth 
and survival of both normal and malignant tissues [7, 8]. 
Prostate epithelium is composed of two histologically distinct layers, a basal cell 
layer and a luminal secretory cell layer. There are at least three distinct major cell types 
in prostate epithelium [9-11]: basal cells, found underlying basal membrane; 
differentiated luminal cells that produce prostatic secretory proteins; and 
neuroendocrine cells scattered between the basal and luminal layers that secrete 
neuroendocrine peptides. The basal layer is the proliferative compartment of the 
prostate epithelium and there is a small subpopulation of basal cells that are thought to 
be true pluripotent stem cells [12-14]. These stem cells give rise initially to the so-called 
transit-amplifying cells that undergo further proliferation and differentiation to 
intermediate epithelial cells that will finally generate the terminally differentiated 
luminal secretory cells. 
Responsiveness of normal and transformed prostate cells to androgenic 
stimulation is determined by the expression of the androgen receptor (AR), a member of 
the nuclear receptor (NR) superfamily of ligand-dependent transcription factors [15]. 
Basal and transit-amplifying cells do not express androgen receptors and intermediate 
cells express AR protein at a very low level, however, all these cells require critical 
levels of androgen-stimulated paracrine growth factors for their proliferation but not for 
survival [11]. AR expression increases all along epithelial cell differentiation process 
reaching a maximum level in terminally differentiated luminal secretory cells. Luminal 
cells are non-proliferating but require constant androgen stimulation for survival [16]. 
Thus, androgen signaling plays a pivotal role in the control of growth, function and 
proliferation of prostate epithelial cells. Androgens are not tumorigenic per se, but they 
are essential for the growth and perpetuation of tumor cells, hence androgen-
suppressing strategies have been widely used for the management of PC since the 
pioneering works of Huggings and Hodges in the early 1940s (reviewed in [17]). The 
most common PC therapy is androgen elimination combined with antiandrogen 
treatment (termed maximal androgen blockade). However, most prostate tumors 
eventually become insensitive to this treatment and recur. The majority of such tumors 
continue to express AR but they are refractory to antiandrogen therapy. One of the 
fundamental challenges for researchers studying PC is understanding the pathways that 
lead to the transition to such so-called androgen independent prostate cancer (AIPC). 
Several mechanisms have been proposed to explain the appearance of AIPC including 
mutations in AR, changes in the levels of AR and/or its coactivators and ligand-
independent activation of AR through crosstalk with other signaling pathways 
(reviewed in [7, 18-20]). Several major signaling pathways have been shown to affect 
AR function, such as growth factor receptor signaling, Mitogen activated protein kinase 
signaling (MAPK), cytokine signaling and Wnt signaling (reviewed in [21]). In recent 
years accumulating evidence suggests that another major signaling pathway, Notch 
signaling, might be tightly intertwined with androgen signaling, contributing directly to 
the regulation of prostate gland development and function. In addition, several 
experimental observations indicate that aberrations in the expression of components of 
the Notch signaling pathway and/or alterations in the molecular mechanisms of 
crosstalk between Notch signals and AR may have a role in the origin and development 
of PC. The purpose of this review is to highlight these recent evidences linking Notch 
and AR regulatory axes and to discuss the possible role for Notch signaling as a 
potential PC therapeutic target. 
 
NOTCH SIGNALING 
Overview of the Notch signaling pathway 
The Notch signaling pathway represents a major regulator of gene expression that 
plays a central role in cell fate decisions in metazoans, acting through local cell-cell 
interactions (reviewed in [22]). Notch ligands and receptors are single-pass 
transmembrane proteins with large extracellular domains. Thomas Hunt Morgan first 
identified notch in 1917 and the gene was named after the notches that appear at the end 
of wing blades of fruit flies lacking a gene copy. Notch receptors and their ligands have 
since been identified in virtually all metazoans. In mammals there are four different 
Notch receptors (NOTCH1-4, [23-27]) and five known Notch ligands named Delta-
like1, -3 and –4 (DLL1, DLL3, DLL4, [28-30]) and Jagged1 and Jagged2 (JAG1 and 
JAG2, [31, 32]). The extracellular domains of all these proteins consist primarily of a 
variable number of epidermal growth factor (EGF)-like repeats responsible for the 
receptor-ligand interaction [33, 34]. The Notch signaling pathway is initiated when 
receptor-bearing cells interact with Notch ligands present on adjacent cells. This leads 
to two consecutive proteolytic cleavage events in the Notch receptor. The first cleavage 
is catalyzed by a member of the ADAM (A disintegrin and metalloprotease) family of 
metalloproteases and it sheds the extracellular portion of the Notch receptor [35]. This 
is followed by the action of gamma-secretase that hydrolyzes a peptide bond within the 
transmembrane domain releasing the Notch intracellular domain (NICD), which then 
translocates to the nucleus [36]. There, NICD binds to a transcriptional regulator known 
as CBF1/Su(H)/LAG-1 (CSL). In the absence of NICD, CSL inhibits expression of 
target genes by recruiting transcriptional corepressors such as NCoR, SHARP and CtBP 
[37, 38]. Interaction with NICD releases these corepressor complexes and allows the 
recruitment of transcriptional coactivators including MAML1 (mastermind-like 1) and 
histone acetyltransferases [39, 40]. The effects downstream of the NICD-CSL 
interaction are not completely understood, but the best characterized target genes 
directly activated by NICD-CSL are members of the bHLH-orange superfamily of 
transcriptional repressors [41-43]. Upon Notch activation the expression of several 
members of this family increases and they modulate cellular responses by suppressing 
expression of downstream target genes, constituting a transcriptional regulatory 
cascade. This is a simplified model of the so-called “classical” Notch pathway, although 
there is evidence for other less understood CSL independent signaling pathways 
triggered by Notch activation designated the “non-classical” pathway. It is beyond the 
scope of this review to describe in detail the complexities of the Notch pathway. 
 
Notch function 
Notch signaling is an evolutionarily conserved mechanism that participates in the 
development of multicellular organisms during embryonic and postnatal development. 
Signals between adjacent cells mediated by Notch receptors are key players in cell fate 
determination, regulating processes such as lateral inhibition and lineage decision in 
tissues derived from all three primary germ layers. Thus, this juxtacrine pathway 
modulates in a precise way other short- and long-range signals required for normal 
development of the organism. During development, phenotypic differences arise in 
neighboring cells, caused by stochastic events, intrinsic or extrinsic factors. These 
subtle differences are stabilized and amplified through changes in expression of Notch 
ligands and receptors, and the downstream intracellular cascades triggered by the 
activation of Notch signals. In addition to their vital role during embryonic 
development, Notch signals regulate the equilibrium between stem-cell maintenance, 
binary cell-fate decisions and induction of differentiation required for homeostasis in 
self-renewing tissues in adult organisms. Due to historic reasons, the roles of Notch 
signaling during embryonic development have been particularly subject to extensive 
characterization, however, subsequent studies have also demonstrated a central role for 
Notch signals in the regulation of other important cellular processes including 
apoptosis, migration, and adhesion, further reinforcing the biological relevance of this 
cell-cell communication mechanism [44, 45]. 
It is noteworthy to mention that the Notch signaling cascade, although very simple 
in the basic core components responsible for the initiation of the signal, which are 
conserved through evolution, can be modulated by signal strength, timing, cell type and 
context. Therefore, Notch activation can have different or even opposing effects 
depending on the cellular context or its integration with other signaling pathways. 
 
The role of Notch in carcinogenesis  
Cancer comprises a group of diseases characterized by an abnormal development 
of cells proliferating in an uncontrolled way. The key role of Notch in the regulation of 
cell proliferation, differentiation and apoptosis make this pathway an obvious candidate 
to participate in the origin and/or progression of tumors when alterations in its normal 
function occur. The first evidence for an oncogenic role of Notch was identified in 
human T-cell acute lymphoblastic leukemia (T-ALL) [46]. The chromosomal 
translocation t(7;9) in human T-ALL results in deregulated expression of a truncated, 
constitutively active NOTCH1 receptor lacking most of its extracellular domain. Recent 
studies have shown that activating mutations of NOTCH1 are present in more than 50% 
of human T-ALLs [47], supporting a critical role for NOTCH1 as an oncogene in this 
type of cancer (reviewed in [48]). The expression of constitutively active NOTCH4 
receptors also causes mammary tumors in mice [26, 49] and activated NOTCH1 
signaling contributes to the neoplastic phenotype in human RAS-transformed cells [50]. 
Although truncated forms of all four Notch receptors have transforming potential in 
vitro [51] and in animal models (reviewed in [52]), oncogenic Notch receptors do not 
usually have full transforming potential and they frequently collaborate with other 
oncoproteins during carcinogenesis. 
To date, gain of function mutations in Notch receptors have not been found in 
human solid tumors. However there is increasing evidence that Notch signals are 
oncogenic in many tissues, and aberrant expression of Notch receptors, ligands, 
modulators and targets has been observed in a growing number of tumors, including 
highly prevalent types of cancer such as breast, lung, prostate, ovarian and pancreatic 
carcinomas [52-54]. 
In keeping with the great context-dependency of the outcome of Notch activation, 
Notch signaling in tumorigenesis is not always associated with an oncogenic role 
induced by its aberrant stimulation. There is clear evidence demonstrating that Notch 
can also act as a tumor suppressor in certain types of cancers [52, 53]), particularly skin 
cancer. In the epidermis, Notch signaling is required for keratinocyte growth arrest and 
entry into differentiation [55]. Moreover, conditional ablation of Notch1 in murine 
epidermis causes epidermal hyperplasia, skin tumors and facilitates chemical-induced 
skin carcinogenesis [56], and transgenic mice expressing a dominant negative form of 
MAML1, a pan-Notch inhibitor, develop cutaneous squamous cell carcinomas [57]. 
These observations indicate an antioncogenic role of Notch signaling in the epidermis. 
Whether this tumor suppressor role of Notch signaling is extended to other tissues 
remains to be established. 
 
NOTCH SIGNALING AND PROSTATE BIOLOGY 
Notch signaling in prostate development 
The first evidences indicating that Notch signaling may be involved in prostatic 
development came from experiments performed with rodent models by Gao and 
colleagues [58]. The previously documented relevance of cell-cell interactions in the 
regulation of proliferation, differentiation and tumorigenesis of prostate epithelial cells 
[6, 59-61] prompted them to study a possible direct role for Notch signaling in the 
regulation of those processes. To do so, they first examined the expression patterns of 
Notch1 mRNA during rodent prostatic development, using quantitative RT-PCR 
analysis and in situ hybridization techniques. These studies on endogenous Notch 
expression were complemented with the characterization of mice containing a transgene 
of green fluorescent protein (GFP) under the control of the Notch1 promoter, wherein 
Notch1-expressing cells fluoresce green [62]. They found that Notch1 was expressed at 
high levels in the developing prostate at postnatal day 1 to postnatal day 10, and its 
expression was down-regulated in adult animals. Before postnatal day 5 all cells in the 
prostatic epithelium possess progenitor cell characteristics, and they observed that all 
these proliferating cells express Notch1 together with cytokeratin-14, a marker for 
epithelial basal cells. From this homogeneous population, some epithelial cells undergo 
differentiation giving rise to the intermediate epithelial cell types and the terminally 
differentiated luminal epithelial cells, which lose cytokeratin 14 expression, whereas 
others remain proliferative and stay in the basal layer. Notch1 expression was only 
maintained in the basal cells, cytokeratin 14-positive cells, indicating that Notch 
expression is associated with the basal cell population. Therefore, NOTCH1 signaling 
might be involved in the acquisition of luminal versus basal cell identity in the prostatic 
epithelium. A similar restriction of NOTCH1 expression to progenitor cells has also 
been described in the nervous system, where NOTCH1 usually is expressed in neural 
progenitor cells but terminally differentiated neurons do not express Notch receptors 
[22]. This study was restricted to a single Notch receptor subtype, but the highly 
regulated dynamics of Notch1 expression strongly suggested a critical role for Notch 
signaling during prostatic development modulating prostate epithelial cell proliferation 
and differentiation. 
Independent studies confirmed that expression of NOTCH1 receptor and its 
ligand Jagged1 is restricted to basal and immature intermediate prostate epithelial cells. 
Tran et al. characterized the phenotype and growth characteristics of human prostate 
epithelial cells growing in vitro [63]. They found that expression of prostate stem cell 
antigen (PSCA), a cell surface antigen expressed in normal prostate epithelial cells that 
is overexpressed in prostate tumors, is a unique marker of late transit-amplifying 
prostate epithelial cells. These cells co-express basal and secretory cytokeratins and 
have a phenotype intermediate between pure basal and secretory cells. Their analysis 
showed that expression of NOTCH1 and Jagged1 is absent in PSCA-positive cells, 
indicating that their expression is restricted to basal and early intermediate precursors. 
Therefore, transit-amplifying cells have heterogeneous phenotypes; NOTCH1 and 
Jagged1 expression is only maintained in a subpopulation of early transit-amplifying 
cells but their expression is lost in more differentiated PSCA-positive cells. 
Further support for a central role of Notch signaling in the control of prostate 
epithelial biology came from recent work by John T. Isaacs and co-workers [64, 65]. 
One of the fundamental constraints for PC research has been the lack of adequate in 
vitro human cell line models. Cells from prostate carcinomas have proven to be one of 
the most difficult cell types from which to establish cell lines. Seventeen human 
prostate carcinoma cell lines have been well-characterized [66], but most in vitro studies 
have been performed using the three earliest established prostate carcinoma cell lines, 
which either contain a mutation in the AR gene that creates a promiscuous AR able to 
bind to and be activated by other steroids (LNCaP), or do not express AR (DU 145 and 
PC-3). These cell models have contributed significantly to our understanding of prostate 
cancer, but they cannot help us to elucidate the molecular pathways responsible for the 
development of PC at its early stages or to explain the causes of the AIPC phenotype 
observed in PC cells still expressing wild-type AR. In attempts to circumvent this 
problem, several groups have established new prostate cancer cell lines from human 
primary prostate tumors using low calcium (<300 µmol/L), serum-free, growth factor-
defined cell culture medium (that is in contrast to previously generated human PC cell 
lines that were originally established with and maintained in 10% fetal calf serum 
medium in which calcium is between 650 and 1,860 µmol/L). Under these culture 
conditions it was documented that from all non-transformed prostate epithelial cell 
populations, only transit-amplifying cells survive and these can be propagated for up to 
10 serial passages [11, 63, 67]. To test whether in those cell culture conditions the non-
transformed transit-amplifying cells derived from normal contaminating prostate 
epithelium were outgrowing cancer cells, Isaacs´ laboratory carried out a thorough 
characterization of prostate cell cultures derived from radical prostatectomy specimens 
[64]. As a result they observed that, in low calcium, serum-free, growth factor-defined 
medium, what grows are not truly prostatic cancer cells but basally derived normal 
transit-amplifying cells. One of the critical reasons that explains the selective outgrowth 
of the normal transit-amplifying versus cancer cells is the differential effect of low-
calcium conditions on the structure of NOTCH1 receptor. As discussed above, basal 
cells and early transit-amplifying cells express the receptor NOTCH1 and its ligand 
Jagged1. In low calcium medium, NOTCH1 receptor is conformationally in a 
constitutively active form allowing cell autonomous signaling independently of cell-cell 
interactions [68]. This ligand independent activation of Notch signaling contributes to 
the survival of transit-amplifying cells even in low cell density cultures. The addition of 
gamma-secretase inhibitors (GSIs) to prostate epithelial cell cultures, at concentrations 
that inhibit the production of the NICD transcription factor, was toxic, and there were 
no viable cells after 5 days of such treatment [64]. These results indicate that survival of 
prostate transit-amplifying cells requires unique NOTCH1 mediated signaling, 
strengthening the notion that Notch signals play an important role in the regulation 
prostate epithelial biology. Their results also suggest that transformed epithelial cells 
either do not express NOTCH1 receptor, or, because of the different cell-context, its 
activation is not sufficient to promote cell survival. At the 1 to 2 mmol/L physiological 
tissue calcium level, NOTCH1 signaling is not cell autonomous and it requires ligand-
dependent activation. Under those conditions NOTCH1 signaling is no longer required 
for survival but instead contributes to stimulate proliferation of prostatic cancer cells. 
The authors of this study suggest that these characteristics are consistent with the ability 
of PC to metastasize to bone, a tissue with high calcium levels. 
 
Mechanisms of crosstalk between Notch and androgen signaling 
More evidence for a possible direct role for Notch signaling in modulating 
prostate physiology derived from biochemical studies performed to characterize the 
molecular mechanism of action of NRs. AR belongs to the NR superfamily of ligand-
dependent transcription factors. The ability of NRs to activate gene transcription 
depends on the recruitment of coactivator protein complexes with enzymatic activities 
that reorganize chromatin. Amongst the best characterized are the p160 family of 
coactivators, SRC1/NCoA1, TIF2/ NCoA2 and AIB1/NCoA3 [69], which interact 
directly with ligand-bound NRs and serve as platform proteins recruiting both enzymes 
that catalyze posttranslational modifications [70] and ATP-dependent-chromatin 
remodeling complexes [71]. A yeast two-hybrid screen performed with the highly 
conserved bHLH-PAS N-terminal domain of SRC1 as bait identified a downstream 
target of Notch signaling, named HEY1 (hairy/Enhancer-of-split related with YRPW 
motif 1), as an SRC1-interacting protein [72]. Upon Notch activation, HEY1 expression 
is increased and it accumulates in the nuclei, acting as a transcriptional repressor of 
Notch target genes. Further functional characterization of this association demonstrated 
that HEY1 interacts directly with both SRC1 and the AR, and specifically represses 
transcription from AR-dependent promoters. Although SRC1 functions as a common 
coactivator for all NRs, HEY1 did not repress any of the other NRs tested. Another 
member of the HEY family that mediates Notch signaling, HEY2, was also able to 
specifically repress AR-dependent transcriptional activity. The mechanisms by which 
HEY1 and HEY2 repress AR, and the functional consequences of this interaction in 
vivo, remain to be elucidated. However, these in vitro experiments suggest that changes 
in endogenous levels of HEY1 in the cell, induced by Notch activation, have the 
potential to modulate cellular responses to testosterone, providing a molecular 
mechanism of coordination between long distance endocrine signals and cell-to-cell 
juxtacrine communication. 
The negative feedback between androgen-dependent signals and Notch pathway 
may possibly occur in a reciprocal manner, based on recent gene profiling experiments 
described by Nantermet et al. [73]. To identify the androgen-responsive genetic 
pathways that regulate prostate cell division and differentiation they examined changes 
in global gene expression in the ventral prostate after DHT administration to androgen-
depleted rats. Among the transcripts expressed significantly differently they observed 
that AR stimulation repressed expression of Notch1 and its ligand Jagged1, also a 
negative regulator of Notch signaling, Sel11 [74], was induced, indicating that DHT 
might inhibit Notch signaling. Their results, on one hand, reinforce the idea that Notch 
signals play a role in the regulation of prostate cell growth and proliferation, and, on the 
other, suggest that in vivo AR stimulation modulates Notch signaling in the prostate 
gland in a negative way. This study, along with the reported repression of AR activity 
by HEY1, a Notch target [72], provides a mechanism for reciprocal negative feedback 
between androgen-dependent gene regulation and Notch. However, these large-scale 
gene expression analysis need to be validated by more experimental evidence and a 
detailed study of the prostate epithelial cell types involved in the crosstalk is lacking.  
In light of recent results from Isaacs laboratory [65], the direct role of HEY1 as an 
AR corepressor may in part explain the molecular mechanisms by which activated 
Notch signaling regulates prostate epithelial cell growth and differentiation. Continuing 
with their characterization of several nonimmortalized and immortalized human prostate 
epithelial cell lines and the consequences of maintaining them in low-calcium medium 
(i.e., subject to continuous, cell autonomous, activation of NOTCH1 receptor), they 
studied the effects of NOTCH1 signaling on differentiation of intermediate cells in 
vitro. These cells fail to undergo full differentiation in vitro into mature, AR-expressing, 
luminal-secretory cells. Such inability is, at least in part, due to the continuous 
activation of NOTCH1 receptor that induces the expression of its downstream effector 
HEY1. HEY1 act as a transcriptional corepressor both for members of the family of 
GATA transcription factors [75, 76] and AR [72]. Thus, it has been proposed that 
HEY1 prevents the expression of GATA- and AR-regulated genes required for further 
differentiation of transit-amplifying cells into luminal-secretory cells. In agreement with 
this observation, human prostate cancer cell lines that are grown in high calcium 
containing medium do not express HEY1, which is consistent with their advanced 
luminal-secretory differentiation status [65]. 
 
Mouse models 
The critical role of Notch signaling in the control of prostate cell growth and 
differentiation suggested by the previously discussed studies, performed using in vitro 
models, has recently been confirmed by using animal models in ex vivo and in vivo 
systems. Wang et al. established a transgenic mouse line in which Notch1-expressing 
cells can be selectively ablated [77]. Specific targeting was achieved by expressing the 
bacterial nitroreductase, an enzyme that catalyzes its substrate into a cytotoxin capable 
of inducing apoptosis, under the Notch1 promoter. Cells that express nitroreductase are 
selectively killed when exposed (in vitro or in vivo) to the prodrug CB1954. This 
experimental approach allowed them to target the cytotoxin to Notch1 expressing cells 
at various developmental time points using two systems: ex-vivo organ culture of early 
postnatal prostates, and in vivo re-growth of prostate in castrated mice following 
testosterone replacement. Their results showed that elimination of Notch1-expressing 
cells inhibited the branching morphogenesis, growth and differentiation of early 
postnatal prostate culture and impaired prostate regeneration triggered by hormone 
replacement in castrated mice. These observations reinforce the idea that NOTCH1-
expressing cells are important for prostate epithelial cell growth and proliferation and 
supported their hypothesis that NOTCH1-positive cells define progenitor cells in the 
prostate epithelium. In addition, they found that NOTCH1 mRNA expression was 
elevated in the prostate following castration but it returned to nearly normal levels after 
3 days of hormone replacement, indicating that the proposed reciprocal negative 
feedback between Notch and androgen signaling [72, 73, 78] may indeed occur in vivo. 
Subsequent studies from the same laboratory further exploited the ex-vivo prostate 
culture model to investigate how inactivation of Notch signaling affects the growth of 
rat neonatal prostate [79]. To do so, they used inhibitors of gamma-secretase, the 
enzyme responsible for the proteolytic step that leads to the generation of NICD. These 
GSIs block the release of NICD and, as a result, prevent the expression of Notch 
downstream effectors [36, 80, 81]. Inactivation of Notch signaling in prostate explants 
greatly enhanced proliferation of prostate epithelial cells but prevented luminal cell 
differentiation. The majority of epithelial cells in prostates treated with GSIs co-express 
cytokeratins 8 and 14, indicating that they are immature progenitor cells and that 
segregation of cytokeratin 8-positive luminal and cytokeratin14-positive basal cells is 
inhibited. These effects on prostate epithelial cell proliferation and differentiation also 
resulted in profound morphologic alterations, causing reduced branching morphogenesis 
and enlarged epithelial tubules in GSI-treated prostate explants. Wang and colleagues 
also used a previously described interferon-inducible Notch1 gene deletion mouse 
model [82] to examine the effect of inactivation of Notch pathway on prostate growth 
and differentiation in vivo. Histological analysis was carried out using prostates 
harvested 3 weeks after Notch1 deletion (at a stage corresponding to postnatal days 36-
40). In Notch1 knockout mice, they observed several significant architectural changes, 
including increased tufting and bridging, and the normal columnar morphology of 
luminal epithelial cells or the laminal nature of basal cells was not properly maintained 
[79]. Moreover, in keeping with the results derived from ex vivo prostate explants, they 
observed an increased epithelial proliferation and enrichment in cell populations that co-
express luminal and basal cell markers. Both experimental approaches have drawbacks, 
because GSIs can affect other biological pathways modulated by gamma-secretases, and 
systemic effects on prostate physiology derived from deletion of Notch1 in all 
NOTCH1-expressing tissues cannot be ruled out, but taken together, these results 
suggest that Notch signaling (i) has an inhibitory role on prostate epithelial cell growth 
and expansion; and (ii) it facilitates proper luminal cell differentiation and epithelial 
layer segregation. Their findings clearly demonstrate that intact Notch signaling is 
required for correct prostate development, although the molecular mechanisms by 
which Notch signals modulate prostate cell proliferation and differentiation are still 
unknown. 
 
NOTCH SIGNALING AND PROSTATE CANCER 
All the experimental evidence described in the previous section indicates that 
Notch signaling plays a key role in the control of proliferation, differentiation and 
survival of prostate epithelial cells. Nearly all prostate adenocarcinomas originate 
within this prostate cell population; therefore it is predictable that alterations in the 
correct function of Notch signaling may contribute to the origin and progression of 
prostate cancer. Indeed, since the early studies linking the Notch pathway to prostate 
physiology, most laboratories working in the field have also characterized the 
expression of components of this pathway in established prostate cancer cell lines and 
human tumor samples, trying to correlate these data with effects on prostate cancer cell 
growth in vitro and in vivo. Below we will summarize the aforementioned studies. 
The initial identification of Notch1 regulated expression during murine prostate 
development prompted Shou and colleagues to examine the expression of Notch1 in 
transgenic adenocarcinoma of the mouse TRAMP prostate cancer model [83]. These 
mice were generated by using the prostate luminal cell-specific rat probasin promoter to 
derive expression of the simian virus 40 large-tumor antigen coding region. Mice 
expressing the transgene display progressive forms of prostatic carcinomas with 
neuroendocrine features. In situ hybridization experiments showed that in TRAMP mice 
normal mature prostate Notch1 expression is either undetectable or very low, but 
malignant and metastatic prostate cells express high levels of Notch1 [58]. A parallel 
study of Jagged1 expression revealed that it was not detectable in the malignant 
epithelial cells in TRAMP tumors or in normal prostatic epithelium in wild-type mice, 
suggesting that in those tumor cells Notch signaling is not physiologically activated, or 
that its activation rely on different ligands or crosstalk with other signaling pathways. 
Notch1 expression is associated with basal cell population during normal prostatic 
development, however, in the malignant cells of TRAMP, Notch1 expression is 
uncoupled from cytokeratin 14, a basal cell marker. This result, together with the 
theoretical luminal-cell specific targeting of probasin promoter, indicate that the 
TRAMP luminal tumor cells could probably undergoing a dedifferentiation process, 
associated with increased proliferation and abnormally elevated Notch1 expression. 
Shou and colleagues also examined expression of Notch1 and its ligands in the 
established human prostate cancer cell lines (LNCaP, DU 145 and PC-3). Notch1 was 
expressed at various levels in these cell lines, showing the highest level in LNCaP cells. 
Conversely, expression levels of Notch ligands are low or undetectable in those cell 
lines. Interestingly, overexpression of the constitutively active form of NOTCH1 
inhibited cell proliferation in all three prostate cancer cell lines [58]. Whether this 
reduction in the proliferation caused by NOTCH1 activation is due to an increase in the 
number of cells undergoing terminal differentiation and becoming mitotically inactive 
remain to be demonstrated. Another independent study showed that NOTCH1 and 
NOTCH2 mRNAs were expressed in prostate cancer cell lines (LNCaP, PC-3 and PC-
3M) whereas NOTCH3 and NOTCH4 mRNAs were not detected [84]. The Notch 
ligands Jagged1, Jagged2 and DLL1 were expressed in all three prostate cancer cell 
lines, and their expression levels were significantly higher in those cell lines relative to 
the levels observed in normal prostate cells (PNT2 cell line). 
Another study has shown that among human prostate cancer cell lines, those with 
osteomimetic properties express higher levels of Notch1 expression [85]. Prostate 
cancer metastasizes preferentially to the skeleton and elicits osteoblastic lesions by 
unknown mechanisms [86], and it has recently been described that Notch signaling 
positively regulates osteoblastic cell differentiation [87]. Based on those evidences 
Zayzafoon and colleagues examined the role of Notch signaling during the development 
of osteomimetic properties of prostate cancer bone metastases [85]. They found that 
NOTCH1 expression is greatly increased (4-5 fold) in two osteoblastic skeletal prostate 
metastatic cancer cell lines (C4-2B and MDA-PCa-2b cells) when compared with non-
skeletal metastatic cancer cell lines (LNCaP and DU 145). Immunohistochemical 
studies showed that NOTCH1 is also expressed in human clinical samples from 
osteoblastic prostate cancer metastasis. NOTCH1 ligand DLL1 was expressed at high 
levels only in C4-2B cells, suggesting that Notch signaling can be activated in this cell 
line without addition of exogenous factors. The expression of other Notch receptors and 
their ligands was also examined but showed no significant correlation between skeletal 
and nonskeletal metastatic cell lines. Using C4-2B cells as in vitro model to study 
mineralization in osteogenic medium they observed that the concomitant activation of 
the ERK and Notch pathways is critical for the ability of prostate cancer metastases to 
acquire osteoblast-like properties. Their results indicate that deregulation of Notch 
pathway may influence prostate cancer cells not only during the initial stages of the 
tumor in the prostate epithelium but also during the establishment of metastatic lesions. 
More evidences for a functional relationship between androgen signals and Notch 
pathways were obtained by Martin et al. [88] by using a high throughput quantitative 
proteomic analysis of proteins secreted by LNCaP cells. This prostate cancer cell line 
was grown in a low protein-defined media under androgen-stimulated and androgen-
starved conditions. Proteomic analysis of the media, verified by Western blot analysis, 
showed that androgens increased the levels of secreted Jagged1 and NOTCH2 
extracellular domains. This observation reinforces the interesting possibility that 
hormone-mediated alterations in the expression of Notch pathway components may 
help to the integration of endocrine signals with cell-to-cell communication dependent 
on Notch receptors. In opposition to the previously discussed data from Nantermet et al. 
[73], which revealed changes in the expression of Notch components induced by 
androgen stimulation in the prostate suggesting an inhibition of Notch signaling, 
activation of androgen receptor in LNCaP cells correlates with an apparent increase in 
Notch signaling. This discrepancy may occur because both studies analyze different 
experimental models (changes induced in vivo in the rat prostate heterogeneous cell 
population versus in vitro effects on the established human LNCaP cell line) but it is 
tempting to speculate that they may reflect alterations in the mechanisms of crosstalk 
between the androgen signaling and the Notch pathway associated with the oncogenic 
phenotype. More research is needed to understand the molecular mechanisms that 
mediate the integration of these two signaling pathways in the prostate. 
Santagata et al. have recently reported the first clinical breakthrough indicating 
that alterations in the expression of some components of Notch signaling are associated 
with prostate cancer in human patients [89]. They carried out an immunohistochemical 
analysis of Jagged1 protein expression in human prostatic specimens, revealing that 
Jagged1 expression was increased significantly in clinically localized prostate cancer 
versus benign prostate tissue. Moreover, Jagged1 staining intensity was also increased 
in metastatic tumor as compared with either clinically localized prostate cancer or 
benign prostate tissue. Therefore, their data demonstrated an association between 
increased Jagged1 expression and progression from localized to metastatic prostate 
cancer (based on immunohistochemical analysis performed in tumor samples from 154 
patients). Interestingly, high Jagged1 expression was significantly associated with 
recurrence, indicating that Jagged1 expression may be a useful marker to facilitate 
differentiating indolent from more aggressive prostate cancer. It is noteworthy to 
mention that in order to reach statistical significance they used only the maximum 
intensity values for each patient, reflecting the heterogeneous nature of prostate cancer. 
Thus, as they suggest, broad tissue sampling may be needed to maximize the possible 
predictive power of Jagged1 expression. In addition to the valuable clinical study, 
Santagata et al. also reported that the intracellular levels of Jagged1 protein in LNCaP 
cells increased after incubation with synthetic androgen analogs, confirming that 
Jagged1 expression increases in androgen-stimulated LNCaP cells [88]. Velasco et al. 
further demonstrated that Jagged1 is an androgen-regulated gene in LNCaP cells by 
using DNA microarray analysis [90]. 
Taken together, the results discussed above suggest that there is a direct impact of 
androgen-dependent signals on the modulation of Notch pathway and dysregulation of 
Jagged1 expression may play a role in prostate cancer cell growth and progression to 
metastatic disease. With the aim to elucidate the mechanistic role of Jagged1 in prostate 
cancer cell growth, Zhang et al. [91] examined the effect of small interfering RNA-
mediated knockdown of Jagged1 in human prostate cancer cell lines, and compared it 
with that of knockdown of NOTCH1 receptor. They monitored the expression of Notch 
ligands in PC-3, DU 145, LNCaP and C4-2B cells by real-time RT-PCR analysis and 
found that Jagged1 and Jagged2 expression were expressed at variable levels whereas 
DLL1 and DLL4 expression were negligible in all four cell lines. Downregulation of 
Jagged1 expression greatly decreased cell growth in those prostate cancer cell lines and 
NOTCH1 siRNA also induced growth inhibition, but to a lesser extent. These results 
add a new layer of complexity to the role of Notch in prostate cancer cells because the 
observed growth-inhibitory effects were independent of the cell line AR status, 
suggesting that Notch signaling impinges on androgen-independent cell growth 
regulatory mechanisms, in addition to its proposed role as a regulator of AR function. 
More in depth analysis of the mechanisms underlying cell growth inhibition in PC-3 
cells depleted of endogenous Jagged1 or NOTCH1 showed that both Jagged1 and 
NOTCH1 siRNA induced S-phase arrest. In the case of Jagged1 knockdown, S-phase 
arrest was associated with reduced CDK2 kinase activity and increased expression of 
the cyclin-dependent kinase inhibitor p27(Kip1), suggesting that one of the mechanisms 
by which Notch signaling controls cell cycle is through regulation of CDK2 activity. 
The downregulation of CDK2 levels and the increase of p27 expression induced by 
Jagged1 siRNA treatment occur mainly at protein level and further studies will be 
required to uncover the detailed cellular pathways modulated by Notch responsible for 
these effects. The stronger growth inhibitory effects of Jagged1 knockdown compared 
to NOTCH1 knockdown suggest that Jagged1 itself could be important in prostate 
cancer cell growth independent of its role as a Notch ligand. 
Belandia et al. [72] recently described further clinical evidence suggesting that 
alterations in Notch signaling may have a role in the aberrant hormonal responses 
observed in prostate cancer. Encouraged by the novel role for HEY1 as an AR repressor 
and the genetic data indicating that amplification of the chromosome region comprising 
HEY1 gene occurs in a large fraction of prostate cancers, and correlates with the 
aggressiveness of tumors [3], they examined HEY1 expression in a series of human 
primary prostate tumors by immunocytochemistry and compared it with benign 
prostatic hyperplasia (BPH) samples. This low-scale expression analysis (24 
independent patients) uncovered a striking difference in the subcellular localization of 
HEY1 in patients with prostate cancer and BPH. The majority of BPH samples showed 
strong nuclear HEY1 staining whereas its expression was restricted to the cytoplasmic 
compartment of prostate carcinoma cells (in 8 out of 10 patients). More cancer samples 
need to be analyzed before these preliminary observations can be generalized, but, if 
HEY1 plays a role in the modulation of AR transcriptional activity in vivo in the normal 
prostate, its nuclear exclusion could contribute to the progression of prostate tumors by 
eliminating Notch-dependent modulation of AR-mediated signaling. In cancer cells 
HEY1 is excluded from the nuclei and therefore it would not repress AR action even 
when its expression is induced upon Notch activation. Moreover, if HEY1 was required 
for the repression of AR in the presence of antiandrogens, its cytoplasmic location may, 
at least in some cases, explain why cancer cells are resistant to antiandrogen treatment. 
Meta-analysis of microarray datasets including tumors, as well as respective 
normal control tissue samples, has revealed that NOTCH1 gene and one of the 
downstream target genes, HEY1, are down-regulated significantly in prostate 
adenocarcinomas [79]. The expression levels of NOTCH1 in 51 prostate tumors were 
significantly lower than normal prostate samples and the mean level of HEY1 
expression was also significantly lower in 93 prostate adenocarcinomas than both 
normal and tumor-adjacent normal tissues. These observations reinforce the idea that 
NOTCH1 and HEY1 may be important in prostate tumorigenesis. 
Finally, additional evidence for dysregulation of Notch1 expression in prostate 
cancer was revealed by expression analysis performed during prostate tumor 
development in the LADY transgenic mouse model [92]. These mice express the large 
T antigen gene, containing a deletion mutation that removes expression of small t 
antigen, under the control of the prostate luminal cell-specific rat probasin promoter 
[93]. As compared with the TRAMP mouse model, tumor progression is less aggressive 
in LADY transgenic mice, but they develop multifocal low-grade PIN that progresses to 
high-grade PIN and early invasive carcinoma with neuroendocrine characteristics but no 
metastasis. NOTCH1 expression increased significantly in the six-week developing 
tumor, but not in the established 16-week tumor [92]. These observations suggest that 
NOTCH1 has an early role in the regulation of prostate epithelial cell proliferation and 
differentiation prior to the appearance of histological changes. Increased NOTCH1 
expression was also found in prostate tumors from TRAMP mouse models [58]. 
However, in this model of prostate carcinogenesis, high NOTCH1 expression is 
maintained even in metastasized tumor cells. This discrepancy between both models 
may reflect the different mechanisms responsible for the oncogenic development and/or 
differences in the strain background between the TRAMP and the LADY models. In 
addition, conversely to the up-regulation of Notch1 expression observed in these SV40 
oncogene-derived mouse models of prostate carcinogenesis, the meta-analysis of human 
prostate adenocarcinoma mentioned above found downregulation of NOTCH1 
expression in human cancer samples [79]. We do not know yet whether these apparently 
conflicting results are caused by a specific characteristic of SV40-derived tumors in the 
mouse models but, independently of the direction of the changes in NOTCH1 
expression, those studies indicate that abnormalities in Notch signaling may be critical 
during the development of prostate cancer. 
 
NOTCH SIGNALING: A POTENTIAL THERAPEUTIC TARGET IN 
PROSTATE CANCER 
Although our knowledge of the biological role of Notch signaling during normal 
prostate development and homeostasis is still preliminary, it is evident that Notch-
mediated signals play an important role in the regulation of prostate cell differentiation 
and proliferation. In addition, a few clinical and experimental evidences point out that, 
in many cases, alterations in the expression of several components of the Notch 
pathway may be associated with the origin or progression of prostate cancer, both in 
mouse models and human primary tumors. Therefore, Notch signaling emerges as a 
novel potential target to design strategies for the treatment of prostate cancer. Inhibition 
of Notch signaling is a therapeutic approach that has been extensively investigated 
during recent years as a novel alternative for the treatment of several malignancies in 
which activation of Notch signals has an oncogenic role. These include T-ALL, breast, 
cervical, endometrial, renal, head and neck squamous cell, pancreatic and lung 
carcinomas and also gliomas, pleural mesotheliomas, melanomas, several types of 
lymphomas, and multiple myeloma (reviewed in [52, 94]). All the experimental 
evidence described in the previous sections indicates that Notch pathway plays a critical 
role in the regulation of prostate epithelial cell fate specification, differentiation and 
proliferation. However, in opposition to the clear oncogenic role of activated Notch 
signaling in other types of cancer, the role of Notch signals during prostate 
tumorigenesis is not yet completely understood, and it may act as a tumor suppressor or 
an oncogenic agent depending on the stage of the disease and/or the type of prostate 
tumor. We have discussed some studies that suggest an oncogenic role for Notch 
signaling in the prostate. For instance, in TRAMP and LADY mice transgenic models, 
NOTCH1 expression is elevated in malignant prostatic epithelial cells [58, 92]. 
Nevertheless, while elevated NOTCH1 expression is maintained in metastasized 
prostate tumor cells in TRAMP mice, NOTCH1 expression seem to be only transiently 
expressed in LADY mice, because the increase in NOTCH1 expression was not found 
in established tumors. The loss of aberrant increased NOTCH expression in established 
tumors could reflect the inability of LADY prostate tumors to metastasize, because 
elevated NOTCH1 expression was also described in osteoblastic skeletal prostate 
metastatic cell lines [85]. Abnormal high expression of other component of the Notch 
pathway, the ligand Jagged1, is associated with prostate cancer metastasis and 
recurrence in humans [89], but we do not know yet whether high Jagged1 expression 
correlates with excessive activation of Notch signaling in those tumors. On the other 
hand, a meta-analysis of microarray data described a significant downregulation of 
NOTCH1 gene in human prostate adenocarcinomas [79]. This type of analysis needs 
further experimental validation, and no significant changes in the expression of other 
Notch pathway genes were found, but this downregulation of NOTCH1 gene may 
indicate a selection in prostate tumors for cells with reduced NOTCH1-dependent 
signaling. Contradictory results have been also obtained when studying the role of 
Notch signaling in the regulation of prostate cancer cell proliferation in vitro. 
Overexpression of a constitutively active form of NOTCH1 inhibited the proliferation 
of various prostate cancer cells, including DU 145, LNCaP and PC-3 cell lines [58]. In 
contrast, siRNA-mediated downregulation of NOTCH1 or Jagged1 also induces cell 
growth inhibition and S phase arrest in the same prostate cancer cell lines [91], and in 
vitro studies with GSIs demonstrated that reduction of Notch signaling induces a 
moderate inhibition of proliferation in LNCaP and DU-145 cells [64]. Even though all 
these studies point to an important role for Notch signaling in the regulation of prostate 
cancer cell proliferation, the complexity of the biological role of Notch signals in the 
prostate cell make it difficult to decipher whether Notch acts an oncogen or a tumor 
suppressor. In addition, these effects occur both in AR dependent and AR-independent 
prostate cancer cell lines, suggesting that besides the previously described crosstalk 
between AR-dependent and Notch signals, Notch also regulates prostate cells by means 
of crosstalk with androgen-independent transduction pathways. 
These seemingly conflicting results surely derive from our incomplete knowledge 
of the role of Notch signaling in the regulation of prostate cell biology. More research is 
needed to gain the information that may help us to understand how alterations in the 
normal function of Notch signals are implicated in the origin and progression of 
prostate cancer. A thorough expression analysis for all Notch receptors, ligands and 
modulators in prostate epithelial cells is still lacking, and more research with prostate 
cancer mice models will undoubtedly help us to understand the role of Notch signals in 
prostate cancer. These animal models will be invaluable to test how modulation of 
Notch activity can be used as a therapeutic tool in prostate cancer. A number of 
strategies for inhibition of Notch signaling have been designed, including antisense 
Notch treatments, monoclonal antibodies, RNA interference, soluble decoy Notch 
inhibitors that sequester Notch ligands and dominant-negative peptides derived from 
MAML1 (reviewed in [52]). Currently, the most advanced strategy for blocking Notch 
signaling is to suppress the proteolytic step that leads to the release of the activated 
intracellular domain of Notch receptors [81]. This step is catalyzed by the gamma-
secretase, a large integral membrane protease complex composed of a catalytic subunit 
(presenilin-1 or presenilin-2) and three accessory subunits (Pen-2, Aph1 and nicastrin 
[36, 95, 96]). This enzyme is also responsible for the proteolytic step that releases the 
amyloid β-peptide, the precursor of amyloid plaques found in the brain of Alzheimer´s 
disease. For that reason, over the past years, a great variety of small molecules of 
pharmaceutical utility have been designed, and already tested in animal models and 
clinical trials, able to inhibit gamma-secretase activity. This preceding research has 
speeded up the initiation of phase 1 clinical trials designed to evaluate the effectiveness 
of one GSI (MK-0752) for the treatment of T-ALL1 and breast cancer2. Due to the 
highly variable nature of prostate cancer tumors we cannot predict the fraction of 
prostate tumors that may be suitable for treatment with GSIs, or at what stage of the 
disease inhibition of Notch signaling may be an useful therapeutic approach. In vitro 
treatment with GSIs seems to increase normal prostate cell proliferation in developing 
prostate grown in culture [79]. However, a similar treatment with GSIs of primary 
cultures of human prostatic transit-amplifying cells established from adult prostate 
induces cell death and, also, a moderate inhibition of cell proliferation in some prostate 
cancer cell lines [64]. These preliminary studies suggest that active Notch signaling 
could be associated with proliferating prostate epithelial cells, implying that inhibition 
of Notch signaling may be a potential treatment aimed to inhibit prostate tumor growth. 
There are several concerns regarding the clinical use of GSIs that should be kept 
in mind: the processing of other gamma-secretase substrates than Notch receptors could 
be affected, the inhibitors could target different types of proteases, and the Notch 
pathway has pleiotropic effects in many different tissues. Thus, toxic side effects may 
sometimes be associated with the clinical use of these compounds. Nonetheless, 
extensive ongoing research in this field, both at pre-clinical stage and in clinical trials, is 
helping to the development of novel classes of GSIs which may help to find a better 
specific treatment for different diseases related to gamma-secretase activity. 
 
CONCLUDING REMARKS 
Although there are still too many questions unanswered, and the available 
fragmentary information does not allow us to predict how widely useful inhibition of 
Notch signaling will be to treat prostate cancer patients, the high prevalence and 
mortality rates of these type of tumors have to drive us to keep working towards 
understanding the role of Notch in prostate cell biology. The findings discussed above 
indicate that expression analysis of components of the Notch pathway in prostate 
tumors may not only help to design novel future therapeutic strategies, but also to be 
used as novel predictive markers useful to manage prostate cancer. Currently, several 
therapies are available for prostate cancer treatment, including radiation therapy, 
chemotherapy, surgery and hormonal therapy. Combined treatments usually work best 
for prostate cancer therapy and the addition to the list of possible treatments of novel 
drugs capable of inhibiting prostate cancer cell proliferation could contribute to the 
design of improved therapeutic protocols. Furthermore, an abnormal crosstalk between 
Notch and androgen-dependent signaling in prostate cancer cells may be one of the 
possible causes for the failure of hormone therapy in some hormone-refractory prostate 
tumors (Fig. (1)). If that hypothesis is true, the combined use of drugs targeting Notch 
signals with anti-androgens may help to obtain better results and overcome the 
resistance to hormonal therapy. An individualized tumor analysis will surely be needed 
to predict the feasibility of the use of inhibition of Notch signaling as an alternative, or 
complementary treatment, as part of a multifaceted attack against the prostate cancer 
cells. The discovery of novel strategies to target hormone-refractory prostate cancer is 
one of the fundamental challenges for researchers in the field and the elucidation of the 
biological role of Notch signaling in prostate cell physiology may help to develop 
combination therapies more effective for the treatment of prostate cancer. 
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ADAM  = A disintegrin and metalloprotease 
AIB1  = Amplified in breast cancer 1 
AIPC  = Androgen independent prostate cancer 
AR  = Androgen receptor 
BPH  = Benign prostate hyperplasia 
CDK2  = Cyclin-dependent kinase 2 
CSL  = CBF-1, suppressor of hairless and LAG-1 
CtBP  = C-terminal Binding Protein 
DLL1  = Delta-like 1 
DLL3  = Delta-like 3 
DLL4  = Delta-like 4 
ERK  = Extracellular signal-regulated kinase 
GFP  = Green fluorescent protein 
GSI  = Gamma-secretase inhibitor 
HEY1  = Hairy/Enhancer-of-split related with YRPW motif 1 
MAML1 = Mastermind-like 1 
MAPK  = Mitogen activated protein kinase 
NCoA1  = Nuclear receptor coactivator 1 
NCoA2  = Nuclear receptor coactivator 2 
NCoA3  = Nuclear receptor coactivator 3 
NCoR  = Nuclear receptor corepressor 
NICD  = Notch intracellular domain 
NR  = Nuclear receptor 
PC  = Prostate cancer 
PIN  = Prostatic intraepithelial neoplasia 
PSCA  = Prostate stem cell antigen 
SHARP  = SMRT/HDAC1-associated repressor protein 
SRC1  = Steroid Receptor Coactivator 1 
SV40  = Simian virus 40 
T-ALL  = T-cell acute lymphoblastic leukemia 
TIF2  = Transcriptional intermediary factor 2 
TRAMP  = Transgenic adenocarcinoma of mouse prostate  
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leukemia/lymphoma (T-ALL) and other leukemias. J. Clin. Oncol. (Meeting abstracts) 
2006, 24, 6585. 
2 Krop, I. E.; Kosh, M.; Fearen, I.; Savoie, J.; Dallob, A.; Matthews, C., Stone, J.; 
Winer, E.; Freedman, S. J.; Lorusso. P. Phase I pharmacokinetic (PK), and 
pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) 
with advanced breast cancer (BC) and other solid tumors. J. Clin. Oncol. (Meeting 
abstracts) 2006, 24, 10574. 
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FIGURE LEGEND 
 
Fig. (1). Schematic diagram of Notch and androgen signaling pathways in the 
prostate epithelial cell; possible integration of both pathways during prostate 
epithelial cell differentiation. Extracellular regions of Notch ligands and receptors 
interact to activate the receptor, eventually leading to the release of the Notch 
intracellular domain (NICD). The NICD then translocates to the nucleus and binds to 
the CSL transcription factor, triggering the transcriptional activation of Notch target 
genes with CSL binding sites (CBS) in their promoters. On the other hand, the androgen 
receptor (AR) is able to respond to changes in the levels of androgens carried in the 
bloodstream. In the presence of androgens, the activated AR moves into the nucleus and 
binds to specific androgen response elements (AREs) present in the promoters of target 
genes, activating their transcription. Other signaling mechanisms, including growth 
factor-, cytokine-, MAPK- and Wnt-dependent signaling also participate in the 
regulation of prostate epithelial cell biology. Therapeutic modulation of Notch pathway 
can in theory be achieved by targeting the interaction between Notch ligands and 
receptors, the proteolytic release of the active NICD or NICD transcriptional functions. 
Prostate cancer hormonal therapy combines androgen elimination with antiandrogen 
treatment. Simultaneous targeting of Notch and androgen signaling pathways may 
potentially improve the outcome of some patients with prostate cancer. Shown below is 
a scheme with the expression profiles of Notch and androgen receptors in normal 
prostate epithelial cells during prostate epithelium differentiation. The relative 
expression levels of elements of both pathways vary during prostate cell epithelial 
differentiation. Prostate tumorigenesis may be associated with abnormal expression of 





































Prostate epithelial cell differentiation!
Basal compartment! Luminal compartment!
Stem cells! Transit-amplifying cells! Intermediate cells! Luminal secretory cells!
MAPK!
Table 1. Notch signaling in prostate development. 
Experimental model Phenotype or findings 
Notch1-GFP transgenic mice Notch1 expression is spatially and temporally regulated during 
prostatic developmenta,b 
Normal human prostate epithelial cell 
cultures 
Notch1 and Jagged1 expression is lost during prostate 
epithelial cell differentiationc 
Human prostate epithelial cells grown in 
low-calcium medium 
Notch1 is required for survival but prevents differentiation of 
transit-amplifying cellsd,e 
Androgen-induced regrowth in the 
castrated rat ventral prostate 
Androgen receptor stimulation in vivo represses Notch 
signalingf 
Selective ablation of Notch1 expressing 
cells in transgenic mice 
Ablation of Notch1-expressing cells inhibits prostatic 
branching morphogenesis during development and regrowth 
following castration and androgen replacementg 
Treatment of ex-vivo prostate explants 
with inhibitors of gamma-secretase 
Inactivation of Notch signaling enhances proliferation but 
prevents differentiation of prostate epithelial cellsh 
Interferon-inducible Notch1 knockout 
mouse model 
Deletion of Notch1 increases epithelial cell proliferation and 
impairs luminal cell differentiationh,i 




Place at the beginning of the “Notch signaling in prostate development” section 
Table 2. Notch signaling in prostate cancer. 
Experimental model Phenotype or findings 
Transgenic Adenocarcinoma of Mouse 
Prostate (TRAMP) model 
Notch1 expression is elevated in malignant prostatic epithelial 
cellsa,b 
Human prostate cancer cell lines 
(DU145, LNCaP and PC-3) 
Constitutive activation of Notch signaling inhibits cell 
proliferationb 
Osteoblastic skeletal prostate metastatic 
cancer cell lines and human clinical 
samples from prostate cancer bone 
metastases 
Notch signaling is required for the development of 
osteomimetic properties in prostate cancer bone metastasesc 
LNCaP cell line Jagged1 is an androgen-regulated gened,e,f 
Tumor and benign prostate samples from 
patients 
High Jagged1 expression is associated with prostate cancer 
metastasis and recurrencef 
Human prostate cancer cell lines 
(DU145, LNCaP, PC-3 and C4-2B) 
Downregulation of Jagged1 induces cell growth inhibition and 
S-phase arrestg 
Human primary prostate tumors and 
benign prostatic hyperplasia samples 
HEY1, a mediator of Notch signaling, is excluded from the 
nuclei in cancer cellsh 
Tumor and benign prostate samples from 
patients 
NOTCH1 and HEY1 genes are significantly downregulated in 
human prostate adenocarcinomasi 
LADY transgenic mouse model of 
prostate cancer 
Notch1 expression is increased in developing tumors but not 
in the established tumorsj 
Footnotes: a[83]; b[58]; c[85]; d[88]; e[90]; f[89]; g[91]; h[72]; i[79]; j[92]. 
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